Document is current
Any future updates will be listed below
-
Authors
Li, Xiaoman S.
Yorston, David https://orcid.org/0000-0001-7259-5320
Steel, David H. https://orcid.org/0000-0001-8734-3089
,
Ellabban, Abdallah A.
Chandra, Aman
Davies, Andrew
Morris, Andrew H. C.
Casswell, Anthony G.
Jalil, Assad
Babar, Atiq
Groenewald, Carl
Goldsmith, Craig
Laidlaw, David Alistair H.
Steel, David H.
Vayalambrone, Deepak
Sanchez-Chicharro, Diego
Casswell, Edward
Hughes, Edward H.
Herbert, Edward N.
Jmor, Fidan
D’Alterio, Francesco Maria
Heimann, Heinrich
Jenkins, Huw
Pearce, Ian A.
Masri, Ibrahim
Khan, Imran
Mitrut, Izabela
Park, Jonathan
Smith, Jonathan
Gonzalez-Lopez, Julio J.
Balaggan, Kamaljit Singh
Cornish, Kurt Spiteri
Wakely, Laura
Membrey, Luke
Chua, Paul Y.
Hillier, Roxane
Hussain, Rumana N.
Cherubini, Sandro Di Simplicio
Tan, Shi Z.
Tarafdar, Sonali
Winder, Stephen
Sandinha, Teresa
Cochrane, Timothy
Williamson, Tom H.
Ivanova, Tsveta
Tanner, Vaughan
- License Information
-
More Information
Article History
Received: 12 November 2025
Revised: 6 December 2025
Accepted: 23 December 2025
First Online: 17 February 2026
Competing interests
: XSL and DY have no disclosures. DHS has received consulting fees from Alcon, BVI, DORC, Roche, Alimera, Eyepoint, Complement Therapeutics, Sitala, AviadoBio, and VascVersa, as well as institutional research funding from Alcon, Bayer, Roche, DORC, BVI, and Boehringer Ingelheim. All funding is unrelated to the current project.
